You are here

P&T News

May 27

Finding may herald emergence of pan–drug-resistant bugs
Probuphine provides low-level buprenorphine for six months
First recombinant factor VIII single-chain therapy
Manufacturing issues sink ZS-9 application

May 26

Class-action complaint alleges misrepresentation, false advertising
Publication outlines implementation strategies in acute care
Approval decision expected in July
If approved, drug would be first single-dose oral therapy for BV

May 25

Implanted rods offer controlled release of buprenorphine
Monoclonal antibody targets nerve growth factor
Advisors voted 7–3 against approval, but patient advocates clamor for a cure
Xaracoll is on schedule for 2017 launch

May 24

If approved, the product would be marketed by Merck
Little is known about potential health risks
Product offers first combination of SGLT2 inhibitor and metformin
Cell-based vaccine is successor to trivalent Flucelvax

Pages